Importantly, the same cannot be said for patients with NSCLC whose extracranial tumors overexpress HER2, for whom ORR and mPFS in the DESTINY-Lung01 trial are closer to historical controls [91,98]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.